Collaborative arrangements (Tables)

6 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Agreement Transaction Price

The following table summarizes the amounts associated with the research activities under the collaboration included in research and development expense or recognized as collaborative arrangement revenue for the three and six months ended June 30, 2021, and 2020 (in thousands):

	For the three months ended June 30,				For the six months ended June 30,
	2021		2020		2021		2020
ASC 808 ide-cel research and development revenue - U.S. (1)(2)	$	—	$	108,196	$	—	$	108,196
ASC 808 ide-cel research and development expense - U.S. (1)	$	(9,193)	$	—	$	(26,018)	$	(5,080)

(1)    As noted above, the calculation of collaborative arrangement activity to be recognized for joint ide-cel efforts in the United States is performed on a quarterly basis. The calculation is independent of previous activity, which may result in fluctuations between revenue and expense recognition period over period, depending on the varying extent of effort performed by each party during the period.

(2)    In the second quarter of 2020, the Company recognized $169.2 million as a cumulative catch-up adjustment to revenue recorded in connection with the May 2020 First Amendment to the Amended and Restated Co-Development, Co-Promote and Profit Share Agreement (“Amended Ide-cel CCPS”), a portion of which was recognized as ASC 808 research and development collaboration revenue. Refer to Note 11, Collaborative arrangements, of the Company’s Annual Report on Form 10-K for further discussion on the Amended Ide-cel CCPS.

The following table summarizes the revenue recognized related to ide-cel ex-U.S. activities for the three and six months ended June 30, 2021, and 2020 (in thousands):

	For the three months ended June 30,				For the six months ended June 30,
	2021		2020		2021		2020
ASC 606 ide-cel license and manufacturing revenue - ex-U.S. (1)	$	4,280	$	73,850	$	9,384	$	87,820

(1)    In the second quarter of 2020, the Company recognized $169.2 million as a cumulative catch-up adjustment to revenue recorded in connection with the May 2020 First Amendment to the Amended and Restated Co-Development, Co-Promote and Profit Share Agreement (“Amended Ide-cel CCPS”), a portion of which was recognized as ASC 606 license and manufacturing revenue. Refer to Note 11, Collaborative arrangements, of the Company’s Annual Report on Form 10-K for further discussion on the Amended Ide-cel CCPS.

Summary of Contract Assets and Liabilities

The following table presents changes in the balances of the Company’s BMS receivables and contract liabilities during the six months ended June 30, 2021 (in thousands):

	Balance at December 31, 2020		Additions		Deductions		Balance at June 30, 2021
Receivables	$	400	$	—	$	(400)	$	—
Contract liabilities:
Deferred revenue	$	26,582	$	—	$	(820)	$	25,762